Experts question stem cell therapy's efficacy in rare kidney disease

09/12/2007 | Forbes

French researchers found no major difference in the survival rate between a group of patients with AL amyloidosis disease who received stem cell transplants and high-dose chemotherapy and those who received standard-dose melphalan-plus-dexamethasone chemotherapy. However, one expert stresses that the overall findings "must be interpreted with caution," adding that the study doesn't disregard that the transplant procedure may be a better option when performed in specialty facilities.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN